Validation Command Center

Multi-agent adversarial consensus · Real-time decision support

12 Active Validations
$4.7B Capital Under Review
89% Avg Consensus
23% Kill Rate
Active Validation Queue — 3 Running
Trial ID: BEACON-GLP1-003
Phase II Metabolic · Novo Nordisk competitor
Asset Value: $380M
PROCEED
94% Consensus
Agent Breakdown
Regulatory
PROCEED
97% No material FDA deficiencies detected
Competitive
PROCEED
91% Pipeline clear for 18+ months
Trial Failure
PROCEED
94% Design matches successful precedent
Capital Risk
PROCEED
93% Downside scenario: $47M / 12% probability
Multi-agent recommendation: PROCEED TO PHASE III 4/4 agents in agreement · Decision confidence: 94%
Trial ID: APEX-KRAS-001
Phase III Oncology · Internal pipeline
Asset Value: $1.2B
DELAY
78% Consensus
Agent Breakdown
Regulatory
DELAY
71% FDA advisory committee precedent unclear
Competitive
PROCEED
96% No competitive threats detected
Trial Failure
DELAY
82% Enrollment rate assumptions 40% optimistic
Capital Risk
DELAY
62% $340M downside if enrollment miss materializes
Dissenting agent: COMPETITIVE (recommends PROCEED) Key risk: Enrollment timeline — recommend 90-day design review before IND filing
3/4 agents in agreement · Decision confidence: 78%
Trial ID: NOVA-CDK4-002
Phase II Oncology · Asset licensing evaluation
Asset Value: $680M
KILL
97% Consensus
Agent Breakdown
Regulatory
KILL
99% Primary endpoint lacks pre-specification
Competitive
KILL
94% 3 competitors at Phase III with same MoA
Trial Failure
KILL
98% 73% structural match to BEACON-CRC failure
Capital Risk
KILL
97% Full capital loss probability: 81%
Pattern matched: “Biomarker Stratification Gap” + “Competitive Crossover Blindspot” 4/4 agents in agreement · Recommendation: DO NOT LICENSE. DO NOT INVEST.
Decision confidence: 97%
Institutional Memory — Active Pattern Library
Pattern Match Database
Biomarker Stratification Gap Oncology · Phase II/III
31 instances Critical
Competitive Crossover Blindspot Oncology · Licensing
24 instances Critical
Enrollment Rate Overestimation All Phases · Design
47 instances High
FDA Advisory Precedent Ambiguity Regulatory · NDA/BLA
18 instances High
MoA Crowding at Late Stage Competitive · Pipeline
12 instances Medium
Pattern Detected in Active Run
Match Confirmed
NOVA-CDK4-002
"Biomarker Stratification Gap"
73% structural similarity to BEACON-CRC failure pattern
Secondary match
"Competitive Crossover Blindspot" — 3 Phase III competitors identified with identical MoA
Kill Decision Basis
The compound structural overlap with a documented failure — combined with a saturated competitive landscape at the same mechanism — exceeds the threshold for capital protection protocols. Dual-pattern match in a single asset is rare: 97% kill consensus is the highest recorded this quarter.
Outcome Accuracy — Validated Predictions
Prediction Accuracy Over Time
Accuracy basis
Measured against confirmed trial outcomes, FDA decisions, and publicly disclosed licensing results. Predictions scored binary: correct or incorrect relative to eventual event outcome.
Capital Protection Ledger
Capital reviewed $4.7B
Capital at risk identified $2.1B
Kill decisions issued 14
Est. capital protected (kills accepted) $890M
Accuracy on accepted kills 92%
$890M in capital protection represents kills where the client accepted the recommendation and the predicted failure subsequently materialized.
Institutional Memory — Live Metrics
Total Validated
 
 
Flagged for Review
 
 
Avg Confidence
 
 
Capital Reviewed
 
 
Recent Validation Runs View Full History →
Submit for Adversarial Review

Submit your next research brief for adversarial review.

Running 4 Adversarial Agents...
Initializing validation engine...
This typically takes 30–50 seconds. Do not close this page.